BEAM-302: Beam’s lead genetic disease program is BEAM-302, a potentially best-in-class liver-targeting LNP formulation of base editing reagents designed to correct the PiZ allele, the most ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback